|
|
||||||||||||
|
Friday, September 16
Study Shows Perils of 'Holiday Heart Syndrome'
by
Alex Hsieh on behalf of Professor Henry Wang
on Fri 16 Sep 2005 12:52 PM EDT
Healthorbit.ca
F.D.A. Data on Defibrillators Expected
by
Alex Hsieh on behalf of Professor Henry Wang
on Fri 16 Sep 2005 12:51 PM EDT
By BARRY MEIER
The Food and Drug Administration plans to release a study that shows that implantable heart defibrillators have been malfunctioning at an increasing rate. Link to Article NYTimes.com
Abbott Gets F.D.A. Approval for Neck Stent With a Filter
by
Alex Hsieh on behalf of Professor Henry Wang
on Fri 16 Sep 2005 12:48 PM EDT
By BARNABY J. FEDER
Abbott Laboratories said it had received approval to sell devices that reduce stroke risk in patients whose neck arteries have been narrowed by a buildup of fatty tissue. Link to Article NYTimes.com
The Vioxx Hex
by
Alex Hsieh on behalf of Professor Henry Wang
on Fri 16 Sep 2005 12:48 PM EDT
PROCEEDINGS began this week in the lawsuit filed by Frederick Humeston of Boise, Idaho, against Merck and Co., the makers of the painkiller Vioxx. Mr. Humeston wants compensation for the heart attack he suffered in 2001, two months after he began to take Vioxx. The facts of the case would seem to give Mr. Humeston little chance. Not only do studies of Vioxx show that the risk of heart attack is linked to use over a much longer term, but Mr. Humeston was, like many other middle-aged men, at risk of a heart attack for other reasons, too.
Unfortunately for Merck, scientific facts didn't play much of a role in the first Vioxx trial, which ended on Aug. 19. The Texas jury in that case awarded $253.4 million to the widow of a man who died of a heart attack triggered by arrhythmia, which is not a condition Vioxx has been proven to cause. The jury, declaring that it wished to "send a message" to Merck, decided to make an enormous symbolic award anyway. Besides, said one juror afterward, the medical evidence was confusing: "We didn't know what the heck they were talking about." Because Texas law limits the size of jury awards, the final cost to Merck is likely to be closer to $2 million. But the precedent set by the jury is ominous. Merck is facing about 5,000 similar lawsuits. If every one of those costs the company $2 million, the total price will come to $10 billion -- if, of course, a company called Merck is still around to pay it. Politicians and regulators should be asking themselves whether a system of massive cash awards to people who may or may not have been adversely affected by Vioxx is a logical, fair or efficient way to run a drug regulatory system. They should also be asking whether juries that scorn medical evidence are the right judges of what information should or should not have been on a prescription label. After all, Vioxx was produced and sold legally. The drug was approved by the Food and Drug Administration, and its label did warn of coronary side effects. It is possible, even probable, that Merck was negligent in its decision to ignore early warnings of the cardiovascular risks of Vioxx. But the company has already paid a price for that negligence, in the losses it has suffered after abruptly taking Vioxx off the market. Fair compensation for the injured needn't entail disproportionate financial punishment as well. In the long term, using the courts to "send a message" to Merck isn't going to help consumers. If the result is an even more cautious FDA approval system and a more cautious pharmaceutical industry, that will keep innovative drugs off the market for much longer. More people will die waiting for new treatments. The cost of producing new drugs will rise dramatically. Already, there are whole areas of medicine -- women's health during pregnancy, for example -- that are made so risky by liability issues that companies may stop doing research in them. The first principle of reforming this system should be that a company that follows the FDA's rather extensive guidelines should be protected from punitive, if not compensatory, damages. At the very least, it is time for Congress to start considering whether a model such as the one set up for children's vaccines -- in which a fund is set up to cover the costs incurred by children harmed by vaccines -- should be constructed for all drugs.
Biotech: Biotech, Pharma Stocks Continue To Rise
by
Alex Hsieh on behalf of Professor Henry Wang
on Fri 16 Sep 2005 12:44 PM EDT
|
Search
Links
|
|||||||||||
